{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:02:31Z","timestamp":1793332951910,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,2,9]],"date-time":"2011-02-09T00:00:00Z","timestamp":1297209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00280-011-1571-6","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T08:41:27Z","timestamp":1297154487000},"page":"971-978","source":"Crossref","is-referenced-by-count":31,"title":["Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors"],"prefix":"10.1007","volume":"68","author":[{"given":"Pin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongguo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,9]]},"reference":[{"issue":"4","key":"1571_CR1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0165-6147(92)90048-B","volume":"13","author":"SB Horwitz","year":"1992","unstructured":"Horwitz SB (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13(4):134\u2013136","journal-title":"Trends Pharmacol Sci"},{"key":"1571_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","volume":"608","author":"AM Gonzalez-Angulo","year":"2007","unstructured":"Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1\u201322","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl. 3","key":"1571_CR3","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1111\/j.1743-7563.2008.00194.x","volume":"4","author":"BH Xu","year":"2008","unstructured":"Xu BH (2008) Epothilones in the treatment of breast cancer: review of clinical experience. Asia-Pac J Clin Oncol 4(Suppl. 3):S30\u2013S39","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"Suppl. 5","key":"1571_CR4","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdm173","volume":"18","author":"P Fumoleau","year":"2007","unstructured":"Fumoleau P, Coudert B, Isambert N et al (2007) Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18(Suppl. 5):v9\u2013v15","journal-title":"Ann Oncol"},{"issue":"10","key":"1571_CR5","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","volume":"22","author":"S Goodin","year":"2004","unstructured":"Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22(10):2015\u20132025","journal-title":"J Clin Oncol"},{"issue":"33","key":"1571_CR6","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210\u20135217","journal-title":"J Clin Oncol"},{"issue":"6","key":"1571_CR7","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1078-0432.CCR-07-2201","volume":"14","author":"JJ Lee","year":"2008","unstructured":"Lee JJ, Swain SM (2008) The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 14(6):1618\u20131624","journal-title":"Clin Cancer Res"},{"key":"1571_CR8","first-page":"275","volume":"66","author":"KH Altmann","year":"2008","unstructured":"Altmann KH, Memmert K (2008) Epothilones as lead structures for new anticancer drugs\u2013pharmacology, fermentation, and structure-activity-relationships. Prog Drug Res 66:275\u2013334","journal-title":"Prog Drug Res"},{"key":"1571_CR9","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdm176","volume":"5","author":"JM Larkin","year":"2007","unstructured":"Larkin JM, Kaye SB (2007) Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol Suppl 5:v28\u2013v34","journal-title":"Ann Oncol Suppl"},{"key":"1571_CR10","doi-asserted-by":"crossref","first-page":"v16","DOI":"10.1093\/annonc\/mdm174","volume":"5","author":"MN Fornier","year":"2007","unstructured":"Fornier MN (2007) Epothilones in breast cancer: review of clinical experience. Ann Oncol Suppl 5:v16\u2013v21","journal-title":"Ann Oncol Suppl"},{"key":"1571_CR11","doi-asserted-by":"crossref","first-page":"v22","DOI":"10.1093\/annonc\/mdm175","volume":"5","author":"NA Dawson","year":"2007","unstructured":"Dawson NA (2007) Epothilones in prostate cancer: review of clinical experience. Ann Oncol Suppl 5:v22\u2013v27","journal-title":"Ann Oncol Suppl"},{"issue":"3","key":"1571_CR12","first-page":"505","volume":"2","author":"S Puhalla","year":"2008","unstructured":"Puhalla S, Brufsky A (2008) Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics 2(3):505\u2013515","journal-title":"Biologics"},{"issue":"10","key":"1571_CR13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3816\/CBC.2007.n.036","volume":"7","author":"MN Fornier","year":"2007","unstructured":"Fornier MN (2007) Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer 7(10):757\u2013763","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"1571_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.18553\/jmcp.2009.15.6.467","volume":"15","author":"J Ho","year":"2009","unstructured":"Ho J, Zhang L, Todorova L et al (2009) Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm 15(6):467\u2013475","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"1571_CR15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263\u20131268","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"1571_CR16","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1177\/10600280940280S507","volume":"28","author":"RS Finley","year":"1994","unstructured":"Finley RS, Rowinsky EK (1994) Patient care issues: the management of paclitaxel-related toxicities. Ann Pharmacother 28(5 Suppl):S27\u2013S30","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1571_CR17","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18(12):2354\u20132362","journal-title":"J Clin Oncol"},{"issue":"3","key":"1571_CR18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdp491","volume":"21","author":"P Schmid","year":"2010","unstructured":"Schmid P, Kiewe P, Possinger K et al (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21(3):633\u2013639","journal-title":"Ann Oncol"},{"issue":"8","key":"1571_CR19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.bjc.6605327","volume":"101","author":"D Arnold","year":"2009","unstructured":"Arnold D, Voigt W, Kiewe P et al (2009) BWeekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101(8):1241\u20131247","journal-title":"Br J Cancer"},{"issue":"9","key":"1571_CR20","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2006.08.7304","volume":"25","author":"C Aghajanian","year":"2007","unstructured":"Aghajanian C, Burris HA 3rd, Jones S et al (2007) Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 25(9):1082\u20131088","journal-title":"J Clin Oncol"},{"issue":"5","key":"1571_CR21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-007-0530-8","volume":"61","author":"T Shimizu","year":"2008","unstructured":"Shimizu T, Yamamoto N, Yamada Y et al (2008) ) Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 61(5):751\u2013758","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1571-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1571-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1571-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T13:13:01Z","timestamp":1637241181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1571-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,9]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1571-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,9]]}}}